Cargando…
Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine
Hepatocellular carcinoma (HCC) accounts for 70–85% of liver cancer, and about 85% of HCC are hepatitis B virus-related (HBV-HCC) in China. Transarterial chemoembolization (TACE) combined with traditional Chinese medicine (TCM) has been reported as an effective treatment. Potential biomarkers to stra...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481798/ https://www.ncbi.nlm.nih.gov/pubmed/34603382 http://dx.doi.org/10.3389/fgene.2021.719451 |
_version_ | 1784576760046682112 |
---|---|
author | Zhou, Guanlin Li, Ying Li, Shicheng Liu, Hongxia Xu, Fei Lai, Xiaohuan Zhang, Qiong Xu, Jingxiang Wan, Shaogui |
author_facet | Zhou, Guanlin Li, Ying Li, Shicheng Liu, Hongxia Xu, Fei Lai, Xiaohuan Zhang, Qiong Xu, Jingxiang Wan, Shaogui |
author_sort | Zhou, Guanlin |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) accounts for 70–85% of liver cancer, and about 85% of HCC are hepatitis B virus-related (HBV-HCC) in China. Transarterial chemoembolization (TACE) combined with traditional Chinese medicine (TCM) has been reported as an effective treatment. Potential biomarkers to stratify patients who may benefit from this treatment are needed. In this study, we aimed to evaluate whether circulating cell-free mitochondrial DNA (ccf-mtDNA) content was associated with the outcome of HCC patients, especially of those who received the combination treatment of TACE and TCM. Univariate and multivariate Cox analyses were conducted to evaluate the association between ccf-mtDNA content and the overall survival of HBV-HCC patients. Kaplan–Meier analysis was used to compare the survival differences between patients with low and high ccf-mtDNA content. In a hospital-based cohort with 141 HBV-HCC patients, there was no statistically significant association between the ccf-mtDNA content and the overall survival of HBV-HCC patients in the univariate analysis, but a borderline significant association was found in the multivariate analyses. In a subcohort of 50 HBV-HCC patients who received TACE and TCM treatment, high ccfDNA content conferred an increased death risk with a hazard ratio of 4.01 (95% confidence interval: 1.25–12.84, p = 0.019) in the multivariate analysis. Kaplan–Meier survival analysis also showed that patients with high ccf-mtDNA content had unfavorable survival (log rank p = 0.097). Our findings suggest that ccf-mtDNA content is a potential non-invasive prognostic biomarker in HCC patients receiving TACE and TCM treatment. |
format | Online Article Text |
id | pubmed-8481798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84817982021-10-01 Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine Zhou, Guanlin Li, Ying Li, Shicheng Liu, Hongxia Xu, Fei Lai, Xiaohuan Zhang, Qiong Xu, Jingxiang Wan, Shaogui Front Genet Genetics Hepatocellular carcinoma (HCC) accounts for 70–85% of liver cancer, and about 85% of HCC are hepatitis B virus-related (HBV-HCC) in China. Transarterial chemoembolization (TACE) combined with traditional Chinese medicine (TCM) has been reported as an effective treatment. Potential biomarkers to stratify patients who may benefit from this treatment are needed. In this study, we aimed to evaluate whether circulating cell-free mitochondrial DNA (ccf-mtDNA) content was associated with the outcome of HCC patients, especially of those who received the combination treatment of TACE and TCM. Univariate and multivariate Cox analyses were conducted to evaluate the association between ccf-mtDNA content and the overall survival of HBV-HCC patients. Kaplan–Meier analysis was used to compare the survival differences between patients with low and high ccf-mtDNA content. In a hospital-based cohort with 141 HBV-HCC patients, there was no statistically significant association between the ccf-mtDNA content and the overall survival of HBV-HCC patients in the univariate analysis, but a borderline significant association was found in the multivariate analyses. In a subcohort of 50 HBV-HCC patients who received TACE and TCM treatment, high ccfDNA content conferred an increased death risk with a hazard ratio of 4.01 (95% confidence interval: 1.25–12.84, p = 0.019) in the multivariate analysis. Kaplan–Meier survival analysis also showed that patients with high ccf-mtDNA content had unfavorable survival (log rank p = 0.097). Our findings suggest that ccf-mtDNA content is a potential non-invasive prognostic biomarker in HCC patients receiving TACE and TCM treatment. Frontiers Media S.A. 2021-09-16 /pmc/articles/PMC8481798/ /pubmed/34603382 http://dx.doi.org/10.3389/fgene.2021.719451 Text en Copyright © 2021 Zhou, Li, Li, Liu, Xu, Lai, Zhang, Xu and Wan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Zhou, Guanlin Li, Ying Li, Shicheng Liu, Hongxia Xu, Fei Lai, Xiaohuan Zhang, Qiong Xu, Jingxiang Wan, Shaogui Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine |
title | Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine |
title_full | Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine |
title_fullStr | Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine |
title_full_unstemmed | Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine |
title_short | Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine |
title_sort | circulating cell-free mtdna content as a non-invasive prognostic biomarker in hcc patients receiving tace and traditional chinese medicine |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481798/ https://www.ncbi.nlm.nih.gov/pubmed/34603382 http://dx.doi.org/10.3389/fgene.2021.719451 |
work_keys_str_mv | AT zhouguanlin circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine AT liying circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine AT lishicheng circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine AT liuhongxia circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine AT xufei circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine AT laixiaohuan circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine AT zhangqiong circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine AT xujingxiang circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine AT wanshaogui circulatingcellfreemtdnacontentasanoninvasiveprognosticbiomarkerinhccpatientsreceivingtaceandtraditionalchinesemedicine |